Literature DB >> 18980979

Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.

Tuya Pal1, Jenny Permuth-Wey, Ambuj Kumar, Thomas A Sellers.   

Abstract

PURPOSE: A meta-analytic approach was used to estimate the frequency of: (a) microsatellite instability-high (MSI-H) phenotype in unselected ovarian cancers and (b) various histologic subtypes of mismatch repair (MMR)-deficient epithelial ovarian cancers.
METHODS: A systematic search of the Medline electronic database was conducted to identify articles published between January 1, 1966, and December 31, 2007, that examined MMR deficiency in ovarian cancers. Data were extracted on the study population, sample size, MSI-H frequency, and histology of MMR-deficient ovarian tumors.
RESULTS: The pooled proportion of MSI-H ovarian cancers was 0.12 [95% confidence interval (CI), 0.08-0.17] from 18 studies with 977 cases. The proportion of histologic subtypes in the pooled analysis from 15 studies with 159 cases was serous at 0.32 (95% CI, 0.20-0.44), mucinous at 0.19 (95% CI, 0.12-0.27), endometrioid at 0.29 (95% CI, 0.22-0.36), clear cell at 0.18 (95% CI, 0.09-0.28), and mixed at 0.24 (95% CI, 0.07-0.47). There was significant heterogeneity between studies.
CONCLUSIONS: The frequency of the MSI-H phenotype in unselected ovarian cancers approximates 12%. MMR-deficient ovarian cancers also seem to be characterized by an overrepresentation of nonserous histologic subtypes. Knowledge of histologic subtype may aid clinicians in identifying the relatively large proportion of ovarian cancers due to MMR defects; such knowledge has potential implications for medical management.

Entities:  

Mesh:

Year:  2008        PMID: 18980979      PMCID: PMC2655731          DOI: 10.1158/1078-0432.CCR-08-1387

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  87 in total

1.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.

Authors:  Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger
Journal:  Epidemiology       Date:  2007-11       Impact factor: 4.822

2.  Combination of log relative risk in retrospective studies of disease.

Authors:  P R Sheehe
Journal:  Am J Public Health Nations Health       Date:  1966-10

3.  The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin.

Authors:  Jeffrey D Seidman; Iren Horkayne-Szakaly; Moutaz Haiba; Charles R Boice; Robert J Kurman; Brigitte M Ronnett
Journal:  Int J Gynecol Pathol       Date:  2004-01       Impact factor: 2.762

4.  Ovarian endometrioma--risks factors of ovarian cancer development.

Authors:  Hiroshi Kobayashi; Kazuhiro Sumimoto; Takashi Kitanaka; Yoshihiko Yamada; Toshiyuki Sado; Mariko Sakata; Shozo Yoshida; Ryuji Kawaguchi; Seiji Kanayama; Hiroshi Shigetomi; Shoji Haruta; Yoriko Tsuji; Sachiyo Ueda; Toshihiko Terao
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-12-26       Impact factor: 2.435

5.  Risk factors for different histological types of ovarian cancer.

Authors:  F Parazzini; F Chiaffarino; E Negri; M Surace; G Benzi; S Franceschi; L Fedele; C La Vecchia
Journal:  Int J Gynecol Cancer       Date:  2004 May-Jun       Impact factor: 3.437

6.  Molecular and clinicopathological analysis of ovarian carcinomas with and without microsatellite instability.

Authors:  Athanassios Dellas; Alex Puhl; Peter Schraml; Sabine E Thomke; Josef Rüschoff; Michael J Mihatsch; Holger Moch
Journal:  Anticancer Res       Date:  2004 Jan-Feb       Impact factor: 2.480

7.  Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.

Authors:  John P Geisler; Michael J Goodheart; Anil K Sood; Richard J Holmes; Melanie A Hatterman-Zogg; Richard E Buller
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

8.  Noncontraceptive estrogen use and the occurrence of ovarian cancer.

Authors:  N S Weiss; J L Lyon; S Krishnamurthy; S E Dietert; J M Liff; J R Daling
Journal:  J Natl Cancer Inst       Date:  1982-01       Impact factor: 13.506

9.  Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.

Authors:  K Domanska; S Malander; A Måsbäck; M Nilbert
Journal:  Int J Gynecol Cancer       Date:  2007-03-05       Impact factor: 3.437

Review 10.  The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer.

Authors:  Janindra Warusavitarne; Margaret Schnitzler
Journal:  Int J Colorectal Dis       Date:  2006-11-16       Impact factor: 2.796

View more
  47 in total

1.  Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry.

Authors:  A Joan Levine; Aung Ko Win; Daniel D Buchanan; Mark A Jenkins; John A Baron; Joanne P Young; Tiffany I Long; Daniel J Weisenberger; Peter W Laird; Rebecca L McCall; David J Duggan; Robert W Haile
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-05

Review 2.  Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America.

Authors:  Megan A Murphy; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2011-04-04       Impact factor: 7.396

3.  MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.

Authors:  Masanobu Takahashi; Minoru Koi; Francesc Balaguer; C Richard Boland; Ajay Goel
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

Review 4.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

5.  Absence of microsatellite instability in mucinous carcinomas of the breast.

Authors:  Magali Lacroix-Triki; Maryou B Lambros; Felipe C Geyer; Paula H Suarez; Jorge S Reis-Filho; Britta Weigelt
Journal:  Int J Clin Exp Pathol       Date:  2010-11-27

6.  Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.

Authors:  Magdalena Koczkowska; Natalia Krawczynska; Maciej Stukan; Alina Kuzniacka; Izabela Brozek; Marcin Sniadecki; Jaroslaw Debniak; Dariusz Wydra; Wojciech Biernat; Piotr Kozlowski; Janusz Limon; Bartosz Wasag; Magdalena Ratajska
Journal:  Cancers (Basel)       Date:  2018-11-14       Impact factor: 6.639

Review 7.  Ovarian cancer in endometriosis: clinical and molecular aspects.

Authors:  B Lyttle; L Bernardi; M E Pavone
Journal:  Minerva Ginecol       Date:  2014-04

Review 8.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Authors:  Valerie Lee; Adrian Murphy; Dung T Le; Luis A Diaz
Journal:  Oncologist       Date:  2016-07-13

9.  Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary.

Authors:  Koah R Vierkoetter; Asia R Ayabe; Maya VanDrunen; Hyeong Jun Ahn; David M Shimizu; Keith Y Terada
Journal:  Gynecol Oncol       Date:  2014-08-02       Impact factor: 5.482

10.  Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.

Authors:  Domenico Coppola; Santo V Nicosia; Andrea Doty; Thomas A Sellers; Ji-Hyun Lee; Jimmy Fulp; Zachary Thompson; Sanja Galeb; John McLaughlin; Steven A Narod; Joellen Schildkraut; Tuya Pal
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.